Literature DB >> 34073529

Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?

Changbo Qu1,2, Gwenny M Fuhler3, Yihang Pan1.   

Abstract

COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; therefore, reducing lung inflammation can undoubtedly benefit the clinical manifestations. Histamine H1 receptor (H1 receptor) antagonists are widely prescribed medications to treat allergic diseases, while recently it has emerged that they show significant promise as anti-SARS-CoV-2 agents. Here, we briefly summarize the novel use of H1 receptor antagonists in combating SARS-CoV-2 infection. We also describe the potential antiviral mechanisms of H1 receptor antagonists on SARS-CoV-2. Finally, the opportunities and challenges of the use of H1 receptor antagonists in managing COVID-19 are discussed.

Entities:  

Keywords:  COVID-19; H1 receptor antagonists; NF-κB signaling; drugs; treatment

Year:  2021        PMID: 34073529     DOI: 10.3390/ijms22115672

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  96 in total

Review 1.  H1-receptors: localization and role in airway physiology and in immune functions.

Authors:  Alkis Togias
Journal:  J Allergy Clin Immunol       Date:  2003-10       Impact factor: 10.793

Review 2.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Authors:  T A Esbenshade; K E Browman; R S Bitner; M Strakhova; M D Cowart; J D Brioni
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

3.  Effects of antihistamines on innate immune responses to severe bacterial infection in mice.

Authors:  Martin Metz; Elizabeth Doyle; Carsten Bindslev-Jensen; Takeshi Watanabe; Torsten Zuberbier; Marcus Maurer
Journal:  Int Arch Allergy Immunol       Date:  2011-02-22       Impact factor: 2.749

4.  Coronavirus 2019, Microthromboses, and Platelet Activating Factor.

Authors:  Theoharis C Theoharides; Smaragdi Antonopoulou; Constantinos A Demopoulos
Journal:  Clin Ther       Date:  2020-08-17       Impact factor: 3.393

5.  COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?

Authors:  Gurusaravanan Kutti Sridharan; Rajesh Kotagiri; Vijay H Chandiramani; Babu P Mohan; Rathnamitreyee Vegunta; Radhakrishna Vegunta; Venkata R P Rokkam
Journal:  Am J Ther       Date:  2020 Jul/Aug       Impact factor: 2.688

6.  Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.

Authors:  Myron S Cohen
Journal:  N Engl J Med       Date:  2020-06-03       Impact factor: 91.245

7.  Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain.

Authors:  Angel Vila-Córcoles; Olga Ochoa-Gondar; Eva M Satué-Gracia; Cristina Torrente-Fraga; Frederic Gomez-Bertomeu; Angel Vila-Rovira; Immaculada Hospital-Guardiola; Cinta de Diego-Cabanes; Ferran Bejarano-Romero; Josep Basora-Gallisà
Journal:  BMJ Open       Date:  2020-12-10       Impact factor: 2.692

8.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

9.  Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.

Authors:  Dong Huang; He Yu; Ting Wang; Huan Yang; Rong Yao; Zongan Liang
Journal:  J Med Virol       Date:  2020-07-14       Impact factor: 20.693

Review 10.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.

Authors:  Qing Ye; Bili Wang; Jianhua Mao
Journal:  J Infect       Date:  2020-04-10       Impact factor: 38.637

View more
  5 in total

Review 1.  Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.

Authors:  Shuai Yang; Ying Tong; Lu Chen; Wenqiang Yu
Journal:  Mol Biomed       Date:  2022-05-20

2.  Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19.

Authors:  Ki-Kwang Oh; Md Adnan; Dong-Ha Cho
Journal:  Curr Issues Mol Biol       Date:  2022-04-08       Impact factor: 2.976

Review 3.  What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders.

Authors:  Enrico Maggi; Bruno Giuseppe Azzarone; Giorgio Walter Canonica; Lorenzo Moretta
Journal:  Allergy       Date:  2021-10-12       Impact factor: 14.710

4.  In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.

Authors:  Luis Heriberto Vázquez-Mendoza; Humberto L Mendoza-Figueroa; Juan Benjamín García-Vázquez; José Correa-Basurto; Jazmín García-Machorro
Journal:  Int J Mol Sci       Date:  2022-04-03       Impact factor: 5.923

5.  Dissecting Physiopathology of COVID-19.

Authors:  Jacek Z Kubiak; Malgorzata Kloc
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.